| Features: organic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Organic Germanium Common names include germanium-132 (Ge-132) and germanium sesquioxide(listed seperately).Small amounts of germanium are found in certain minerals and plant products, including: argyrodite germanite garlic ginseng aloe comfrey "At present, germanium is widely recognized as a vital trace element, which is particularly essential for the normal functioning of the immune system and plays a significant role in cancer prevention"(note this statement is not universally accepted) Organogermanium / Ge-132 / propagermanium — comprises synthetic carbon-containing germanium compounds based on carboxyethylgermanium or oxygermylpropionic-acid structures. Ge-132, formally poly-trans-[(2-carboxyethyl)germasesquioxane] and commonly called carboxyethylgermanium sesquioxide or bis(2-carboxyethylgermanium) sesquioxide, hydrolyzes in aqueous environments to 3-(trihydroxygermyl)propanoic acid. Propagermanium is the pharmaceutical 3-oxygermylpropionic acid polymer and is marketed in Japan as Serocion for selected HBe-antigen-positive chronic hepatitis B patients. Ge-132 and propagermanium are closely related organogermanium preparations but should not be assumed to be chemically, pharmaceutically or clinically interchangeable with every product marketed as “organic germanium.” Purified organogermanium has substantially lower experimental renal toxicity than germanium dioxide, but germanium is not an essential nutrient and product contamination with inorganic germanium remains an important safety concern. Primary mechanisms (ranked):
Bioavailability / PK relevance: Ge-132 and propagermanium produce measurable systemic germanium exposure after oral administration but have preparation-specific pharmacokinetics. After very large single Ge-132 doses in healthy volunteers, peak plasma germanium occurred within approximately 0.75–2 hours and the terminal half-life was approximately 5–6 hours, while less than 11% of the administered germanium was recovered in urine within 24 hours. Pharmaceutical propagermanium at a 15 mg single dose reached peak plasma concentration near 3 hours with a half-life near 2.4 hours; its structural unit was reportedly not metabolized, and urinary and fecal elimination were substantial. Because renal clearance contributes materially, exposure may increase with severe renal impairment. In-vitro vs systemic exposure relevance: Ge-132 is hydrolyzed in water and biological fluids, so experiments using Ge-132 or its hydrolysate must be interpreted according to the actual chemical species and concentration present. Antioxidant, sulfide-binding and cis-diol-complex experiments commonly use micromolar-to-millimolar concentrations that may exceed exposure from ordinary supplement use. The CCL2-related oncology rationale is not primarily based on direct tumor-cell cytotoxicity; it depends on modulation of monocytes, macrophages, myeloid-derived suppressor cells and the tumor microenvironment. Clinical evidence status: Preclinical for anticancer efficacy, with limited Phase I human oncology evidence. A perioperative dose-escalation study in 12 patients with primary breast cancer found propagermanium doses of 30–90 mg/day feasible without dose-limiting toxicity, but it was not designed to demonstrate reduced recurrence, metastasis or survival benefit. A single historical remission report involving oral germanium sesquioxide cannot establish causality. Propagermanium has prescription-drug status in Japan for improvement of viral markers in selected HBe-antigen-positive chronic hepatitis B, not for cancer. No validated randomized cancer trial supports Ge-132 or propagermanium as an anticancer treatment or adjunct. Organogermanium Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Type: effect | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The Warburg effect (aerobic glycolysis) is a metabolic phenotype where many cancer cells use high glycolytic flux and lactate production even when oxygen is available. Tumors often contain hypoxic regions that further drive glycolysis, but Warburg metabolism can also occur under normoxic conditions (“pseudo-hypoxia”) via oncogenic signaling and metabolic rewiring. Hypoxia-inducible factor 1 alpha (HIF-1α) is one important driver in hypoxic tumor regions. HIF-1α upregulates glycolytic genes (e.g., GLUT1, HK2, LDHA) and promotes reduced mitochondrial pyruvate oxidation in part through induction of PDK (which inhibits PDH), shifting carbon toward lactate. Warburg effect (GLUT1, LDHA, HK2, and PKM2).Classic HIF-Warburg axis: PDK1 and MCT4 (SLC16A3) (pyruvate gate + lactate export). Here are some of the key pathways and potential targets: Note: use database Filter to find inhibitors: Ex pick target HIF1α, and effect direction ↓ 1.Glycolysis Inhibitors:(2-DG, 3-BP) - HK2 Inhibitors: such as 2-deoxyglucose, can reduce glycolysis -PFK1 Inhibitors: such as PFK-158, can reduce glycolysis -PFKFB Inhibitors: - PKM2 Inhibitors: (Shikonin) -Can reduce glycolysis - LDH Inhibitors: (Gossypol, FX11) -Reducing the conversion of pyruvate to lactate. -Inhibiting the production of ATP and NADH. - GLUT1 Inhibitors: (phloretin, WZB117) -A key transporter involved in glucose uptake. -GLUT3 Inhibitors: - PDK1 Inhibitors: (dichloroacetate) - A key enzyme involved in the regulation of glycolysis. PDK inhibitors (e.g., DCA) activate PDH and shift pyruvate into TCA/OXPHOS, reducing lactate pressure. 2.Pentose phosphate pathway: - G6PD Inhibitors: can reduce the pentose phosphate pathway 3.Hypoxia-inducible factor 1 alpha (HIF1α) pathway: - HIF1α inhibitors: (PX-478,Shikonin) -Reduce expression of glycolytic genes and inhibit cancer cell growth. 4.AMP-activated protein kinase (AMPK) pathway: -AMPK activators: (metformin,AICAR,berberine) -Can increase AMPK activity and inhibit cancer cell growth. 5.mTOR pathway: - mTOR inhibitors:(rapamycin,everolimus) -Can reduce mTOR activity and inhibit cancer cell growth. Warburg Targeting Matrix (Cancer Metabolism)
Time-Scale Flag (TSF): P / R / G
|
| 7124- | Ge-132, | Physiological Activity of Trace Element Germanium including Anticancer Properties |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:429 Target#:947 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid